BUSERELIN IN PREMENSTRUAL-SYNDROME

Buserelin, a luteinizing hormone releasing hormone agonist was administered nasally in doses of 900-mu-g daily to inhibit the ovarian cycle. Of 16 patients recruited, ten completed the treatment. Daily symptoms were measured on the Visual Analogue Scale and Trigg's trend analysis utilized for the analysis. The peak severity of symptoms (ESA(max)) and the maximum global scores (G(max)) reduced on buserelin treatment. The minimum global scores (G(min)) and the minimum score for each symptom (ESA(min)) increased, suggesting worsening of underlying symptoms. The difference between ESA(max) and ESA(min) (ESA(delta)) and G(max) and G(min) (G(delta)) were calculated to determine the degree of symptom change. The delta scores for symptoms of depression, bloatedness and breast symptoms, and G(delta) were significantly reduced (p < 0.05) on buserelin, whilst the latter significantly worsened in the follow-up months. Side-effects may limit the place of buserelin in the long-term treatment of premenstrual syndrome, although combination of additional hormonal treatment may facilitate long-term treatment.